Skip to main content

Table 3 Haplotype frequencies of TRIM22 rs1063303 and rs7113258 polymorphisms and their genetic association with significant fibrosis (F ≥ 2) at baseline and sustained virological response (SVR) in HIV/HCV coinfected patients on HCV therapy

From: Relationship of TRIM5 and TRIM22 polymorphisms with liver disease and HCV clearance after antiviral therapy in HIV/HCV coinfected patients

Haplotypes by fibrosis

Frequency

OR (95 % CI)

p valuea

aOR (95 % CI)

p valueb

F < 2 (%)

F ≥ 2 (%)

CT

49.5

47.0

0.88 (0.61–1.28)

0.509

0.91 (0.62–1.34)

0.627

GT

34.8

35.7

1.05 (0.71–1.55)

0.818

1.03 (0.68–1.54)

0.902

GA

8.6

8.2

0.94 (0.46–1.95)

0.876

0.88 (0.41–1.89)

0.749

CA

7.1

9.1

1.43 (0.69–2.95)

0.321

1.52 (0.68–3.37)

0.294

Haplotypes by HCV

treatment response

Non-SVR (%)

SVR (%)

OR (95 % CI)

p valuea

aOR (95 % CI)

p valueb

CT

50.7

46.5

0.82 (0.58–1.15)

0.244

0.78 (0.51–1.18)

0.236

GT

36.5

33.3

0.84 (0.58–1.21)

0.345

0.86 (0.55–1.34)

0.496

GA

7.0

10.0

1.81 (0.90–3.61)

0.090

1.61 (0.67–3.88)

0.286

CA

5.9

10.2

2.29 (1.12–4.70)

0.018

2.80 (1.19–6.57)

0.013

  1. Statistically significant differences are shown in italics
  2. aOR adjusted odds ratio; 95 %CI 95 % confidence interval; SVR sustained virological response; HCV hepatitis C virus; HIV human immunodeficiency virus
  3. ap values were calculated by Chi square tests
  4. bp values were calculated by logistic regression adjusting for the most important clinical and epidemiological characteristics (see ‘‘statistical analysis’’ section)